Finally, our Chronic Disease Support webinar on Ivermectin is published.
Here are some references that give different views on this drug. Please make your own decision on its use. However, the main purpose of Ivermectin is anti-parasitic. Consider this from the CDC published on May 8, 2014:
Most people think parasitic diseases occur in poor and developing countries, or are infections they might pick up on a trip to a foreign country. However, parasitic infections also occur in the United States, and in some cases affect millions of people. Often they can go unnoticed, with few symptoms. But many times the infections cause serious illnesses, including seizures, blindness, pregnancy complications, heart failure, and even death. Anyone—regardless of race or economic status—can become infected.
• Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro.
• A single treatment able to effect ~5000-fold reduction in virus at 48 h in cell culture.
• Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing.
• Ivermectin is widely available, due to its inclusion on the WHO model list of essential medicines.
This report gives a more cautious view...
In summary, there is equipoise. This is a term used in bioethics to define a situation in which there is reasonable doubt of whether a drug might be of use or not. Testing of ivermectin against SARS-CoV-2 in clinical trials is warranted.
This site is completely in line with the NIH stance on COVID-19 Treatment Guidelines as of 2/11/2021.
This data is from the Frontline Critical Care doctors. Note they used hydroxychloroquine in conjunction with ivermectin in this study.
Marik and colleagues also described a randomized controlled trial of hospitalized patients that was done concurrently with the prophylaxis study. The trial included 400 patients split into four groups — two consisting of patients with mild to moderate illness and two consisting of severely ill patients. Patients with mild to moderate illness received one dose of ivermectin per day in addition to standard care or hydroxychloroquine twice a day in addition to standard care. The researchers determined that the rate of illness progression was significantly lower among those who received ivermectin (1% vs. 22%). Severely ill patients were assigned to receive standard care plus ivermectin or hydroxychloroquine. The researchers determined that in addition to lower rates of COVID-19 illness progression in the ivermectin group (4% vs. 30%), the ivermectin group also had a lower mortality rate (2% vs. 20%).
Please visit the FLCCC Alliance website for updates on the battle against COVID-19
Look below to find the times and links our weekly webinars....
What is the Chronic Disease Support program?
1. It is a weekly live, interactive, 1h, webinar on Zoom covering important health-related topics.
2. The schedule is Mondays at 12 noon EST and Tuesday at 8 pm EST. The topic is the same at both times/dates. We offer 2 times per week to accommodate schedules.
Monday Zoom link (noon EST):
Tuesday Zoom link (8pm EST):
copy and paste to your browser at the designed time to join.
Archived videos are found at https://www.youtube.com/channel/UCd_LYVg22017AkE1GfKa4_A